US EditionNagase Viita to Launch SUCROSE SG, an Injectable-Grade Pharmaceutical Excipient, in 2025 - Pharma Excipients
Summary by Pharma Excipients
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Nagase Viita to Launch SUCROSE SG, an Injectable-Grade Pharmaceutical Excipient, in 2025 - Pharma Excipients
PRESS RELEASE Nagase Viita Co., Ltd. (Headquarters: Shimoishii, Kita-ku, Okayama; Representative Director: Naoki Yasuba), a member of the NAGASE Group, is set to expand the line of SOLBIOTETM, saccharide-based pharmaceutical excipients, with the launch of high-purity and low-endotoxin SUCROSE SG by June 2025. The portfolio of SOLBIOTETM includes TREHALOSE SG and MALTOSE PH which are the signature products of pharmaceutical ingredients, and with …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
